Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Norway / NCT02690441
Active, not recruiting Not applicable

Physical Exercise Augmented CBT for GAD

NCT02690441 · tracked via the Priya Life Science Norway tracker
Phase
Not applicable
Started
2016-03
Last updated
2026-04-28

Condition(s) studied

Generalized Anxiety Disorder

Investigational drug(s) / intervention(s)

Cognitive Behavioural TherapyPhysical ExercisePlacebo control

Cognitive Behavioural Therapy: Cognitive behavioural therapy conducted individually. 10 weekly sessions, first session lasts 90 minutes, the remaining sessions last 45 minutes.

Physical Exercise: Manualised exercise. 15 weekly sessions with instructor, and two weekly unsupervised sessions performed individually.

Placebo control: One follow-up telephone call à 15 minutes each week for 15 weeks. Aims to control for therapist contact in physical exercise condition and total duration of treatment.

Study summary

Generalised anxiety disorder (GAD) is a severe and debilitating anxiety disorder that is highly prevalent among older adults. Anxiety and GAD is a well-documented risk factor for the development of other severe conditions such as depression and dementia, and effective treatments are called for. However, recommended treatment for GAD has consistently been found to yield blunted response rates for older adults compared to younger patients.

The purpose of this study is to evaluate the effects of exercise-augmented cognitive behaviour therapy for older adults with GAD. Exercise augmented CBT is expected to yield better results than standard CBT in terms of greater reduction of symptoms and increased rates of remission. The investigators will also investigate the effects of treatment on biological, physiological and neuropsychological measures.

Eligibility

Sex
ALL
Min age
60 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Primary diagnosis of GAD Exclusion Criteria: * Substance abuse * Use of benzodiazepines, use of antipsychotica * Lack of ability to stabilize other psychotropic medication during participating in the study * Medical condition that precludes participation in physical exercise * Severe major depression as determined by the MINI International Neuropsychiatric Interview * Life-time history of psychosis and/or mania * Participation in other ongoing psychotherapy * Organic brain disease * Positive screening for dementia with Mini Mental State Examination * Currently engaged in a regular physical exercise program

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Solli DPS Bergen Nesttun

More Solli Distriktspsykiatriske Senter trials in Norway

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02690441 on ClinicalTrials.gov ↗ ← All trials in Norway